These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 33848541)
1. Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. Sheikh Z; Bradbury P; Reekie TA; Pozzoli M; Robinson PD; Kassiou M; Young PM; Ong HX; Traini D Eur J Pharmacol; 2021 Jul; 902():174098. PubMed ID: 33848541 [TBL] [Abstract][Full Text] [Related]
2. An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. Sheikh Z; Bradbury P; Pozzoli M; Young PM; Ong HX; Traini D Eur J Pharm Biopharm; 2020 Nov; 156():121-130. PubMed ID: 32916267 [TBL] [Abstract][Full Text] [Related]
3. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia. Law JP; Wood AJ; Friman VP Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898 [TBL] [Abstract][Full Text] [Related]
4. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment. Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333 [TBL] [Abstract][Full Text] [Related]
5. Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin. Wollstadt A; Krämer I; Kamin W Pharmazie; 2013 Sep; 68(9):744-8. PubMed ID: 24147342 [TBL] [Abstract][Full Text] [Related]
6. [Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients]. Quintana-Gallego E; Lopez-Campos JL; Calero C; Dapena FJ Med Clin (Barc); 2014 Jan; 142(2):59-63. PubMed ID: 23369499 [TBL] [Abstract][Full Text] [Related]
7. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010 [No Abstract] [Full Text] [Related]
8. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. Schülin T J Antimicrob Chemother; 2002 Feb; 49(2):403-6. PubMed ID: 11815589 [TBL] [Abstract][Full Text] [Related]
10. In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients. Hector A; Kappler M; Griese M Mediators Inflamm; 2010; 2010():809591. PubMed ID: 20634941 [TBL] [Abstract][Full Text] [Related]
11. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase). Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442 [TBL] [Abstract][Full Text] [Related]
12. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis. Antoniu S Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312 [TBL] [Abstract][Full Text] [Related]
13. Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin. Müller L; Murgia X; Siebenbürger L; Börger C; Schwarzkopf K; Sewald K; Häussler S; Braun A; Lehr CM; Hittinger M; Wronski S J Antimicrob Chemother; 2018 Oct; 73(10):2762-2769. PubMed ID: 29982453 [TBL] [Abstract][Full Text] [Related]
15. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Hodson ME; Gallagher CG; Govan JR Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344 [TBL] [Abstract][Full Text] [Related]
16. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647 [TBL] [Abstract][Full Text] [Related]
17. A demonstration of the susceptibility of clinical isolates obtained from cystic fibrosis patients to manuka honey. Jenkins R; Wootton M; Howe R; Cooper R Arch Microbiol; 2015 May; 197(4):597-601. PubMed ID: 25680398 [TBL] [Abstract][Full Text] [Related]
18. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study. Millar BC; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786 [TBL] [Abstract][Full Text] [Related]
19. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995 [TBL] [Abstract][Full Text] [Related]
20. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Craparo EF; Porsio B; Schillaci D; Cusimano MG; Spigolon D; Giammona G; Cavallaro G Nanomedicine (Lond); 2017 Jan; 12(1):25-42. PubMed ID: 27879162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]